Gencurix Inc
229000
Company Profile
Business description
Gencurix Inc develops diagnosis treatment kits. The company focuses on developing molecular diagnostic tests based on core technologies of liquid biopsy and biomarker discovery. It offers products including GenesWell BCT, a breast cancer test, GenesWell ddEGFR Mutation Test, Droplex, eDX, Geno CTC, and others.
Contact
243 Digital-ro
15th floor, Jiha City
Guro-gu
Seoul
KORT: +82 7074329481
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,986.10 | 15.90 | 0.18% |
| CAC 40 | 8,157.82 | 69.50 | -0.84% |
| DAX 40 | 24,128.98 | 26.47 | -0.11% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,379.08 | 77.93 | -0.75% |
| HKSE | 25,911.02 | 67.05 | -0.26% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 60,443.15 | 726.97 | 1.22% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 56.68 | 0.80% |
| S&P/ASX 200 | 8,761.30 | 12.10 | 0.14% |
| SSE Composite Index | 4,084.59 | 4.69 | 0.12% |